NDC product
Valganciclovir hydrochloride for Oral
NDC 0591-2579 · Actavis Pharma, Inc.
Key facts
| Product NDC | 0591-2579 |
|---|---|
| Proprietary name | Valganciclovir hydrochloride for Oral |
| Nonproprietary name | Valganciclovir hydrochloride |
| Substances | VALGANCICLOVIR HYDROCHLORIDE |
| Dosage form | POWDER, FOR SOLUTION |
| Route | ORAL |
| Labeler | Actavis Pharma, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA205220 |
| Pharmacologic classes | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], DNA Polymerase Inhibitors [MoA], Nucleoside Analog Antiviral [EPC], Nucleoside Analog [EXT] |
| Marketing start | Aug 26, 2016 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: